Medsolve Dynamics

Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology. medsolvedynamics.com | [email protected] #AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations

Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply. medsolvedynamics.com | [email protected] #Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations

AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo. medsolvedynamics.com | [email protected]  #RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out. medsolvedynamics.com | [email protected]  #Theranostics #RadiationOncology #RadiopharmaceuticalTherapy #OncologyOperations

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affecting the curative schedule. medsolvedynamics.com | [email protected]  #RadiationOncology #Osteoarthritis #ServiceLineGrowth #BenignDisease

Most rad onc programs walk into a service contract renewal with no independent numbers on the table. The vendor brings their performance data. The program nods. The renewal runs the vendor's direction. The gap is not in the contract language. It is in the measurement asymmetry. Five metrics the vendor tracks and the program rarely does. Uptime delivered against contracted spec. Response time against contracted SLA. Preventive maintenance hours delivered against contracted hours. Parts coverage against parts billed extra. First-call resolution rate. Pull the data quarterly, reconcile against contract spec, build the quarterly service review around the gap.medsolvedynamics.com  |  [email protected]

At ESTRO 2026, United Imaging showed a CE-marked uRT-linac 506c on the show floor. Diagnostic-CT integrated with a linear accelerator on a single platform. Online adaptive radiotherapy positioned without an MR-linac, without a third-party planning system, and without RaySearch. Reported as CE marked in Europe. Not yet in the US market. Capital decisions in flight in the US in 2026 are not changing because of what showed up in Berlin. What changed is the leverage map on every conversation around them.medsolvedynamics.com  |  [email protected]

Most rad onc programs sitting on soft Q2 numbers are looking outside the building for offsetting revenue. The infrastructure for radioligand therapy is already inside the building, and a Jefferson-authored paper accepted by Practical Radiation Oncology in May 2026 puts the 340B-eligible hospital gross margin at roughly $101,000 per Pluvicto patient over a full course. The same paper names why programs stall. The rad onc on a dollars-per-wRVU comp model takes a 26-wRVU haircut against EBRT for picking up RPT. The credential map is already in the department. The comp model discussion is in the way. The operator move is to renegotiate the comp model with the 340B margin as the leverage before the service line gets approved.medsolvedynamics.com | [email protected]

From 20 years on the vendor side of oncology software sales, the one question that exposes the AI price premium baked into software renewal quotes in 2026. Treatment planning systems, contouring software, registry products, SaaS modules. The AI features were priced higher than the same software would have priced two years ago. Get the unbundled price. medsolvedynamics.com | [email protected]

A vendor-side story Yoel Bakas has watched play out dozens of times in radiation oncology. A software demo runs without anyone asking what is actually broken in the customer's workflow. The tool gets relabeled AI-enabled a year later. Until the customer understands what is broken, it does not matter what the tool is. AI in radiation oncology, workflow design, vendor evaluation, capital decision. medsolvedynamics.com | [email protected]

From 20 years on the vendor side of LINAC capital and service negotiations, the data point most radiation oncology programs do not see with the same precision the vendor sees it: their own unbooked machine hours. Every unbooked hour is a fixed cost paid for and not recovered. The 15-minute utilization audit is the cheapest margin discipline in the 2026 reimbursement environment. medsolvedynamics.com | [email protected]

Capital decisions hold up when the year-five reality is considered before the signature. They break when only year-one numbers are. From 20 years on the vendor side and now on the program side, the year-five question that protects margin through a multi-year operating commitment in radiation oncology. medsolvedynamics.com | [email protected]

From 20 years on the vendor side and now on the program side, the math that wins capital approval is not the math the program runs in year two. The reimbursement environment moved more than the headline rate change. medsolvedynamics.com | [email protected]

Benign disease radiation uses LINAC capacity that is already paid for in most programs. The growth question is referral pathway, not capital. From 20 years of watching programs add and grow service lines. medsolvedynamics.com | [email protected]

From 20 years on the vendor side and now on the program side, the capital form decision that gets skipped on most theranostics service-line additions. Build or partner sets the next decade. With reference to Kenneth Brooks and Christine Stone’s published build case study at Wellstar Health System. medsolvedynamics.com | [email protected]

Capital decisions in radiation oncology are not point-in-time decisions. The proforma that wins approval at signature is not the proforma that runs the program in year five. From 20 years on the vendor side and now on the program side, the math that protects margin through a full capital cycle. medsolvedynamics.com | [email protected]

A moment from the AMAC Spring Symposium 2026 talk on the day I told a room of oncology administrators that I have watched programs lose margin on contracts I helped sell them. Plus the 17-year ROI case study. medsolvedynamics.com | [email protected]

A short clip from the AMAC Spring Symposium 2026 talk on the discipline programs need to apply to every capital decision in the current environment. Forward-looking, not policy-blame. medsolvedynamics.com | [email protected]

The capital case in a vendor proforma is usually solid. The operating case is rarely modeled. From 20 years on the vendor side selling these programs, here is the operational reality that shows up in year two and never lives in the original proforma. Applies to LINAC purchases, theranostics expansions, and benign disease program builds. medsolvedynamics.com | [email protected]

Jeff Siupik, 35 years in oncology operations, on where volume responsibility actually belongs in a healthy program. The C-suite looks at P&L. The clinical team looks at compassionate care. Where leaders most often misallocate the volume expectation, and where it should sit instead.Full episode: https://youtu.be/9bPM8rjsv6Ymedsolvedynamics.com | [email protected]#RadiationOncology #OncologyLeadership #HealthcareExecutive #OncologyOperations

Yoel Bakas sits down with Jeff Siupik, a healthcare executive with 35 years in oncology operations and 25 years in oncology leadership. Jeff has put in eight to ten linear accelerators across his career, led oncology programs through every reimbursement shift since the early 1990s, and currently oversees operations across a multi-program system.The conversation walks through the actual job of an oncology administrator in 2026.The balance between growth and expense control. Why P&L looks worse before it looks better when a program is in growth mode, and what most administrators are explaining to finance committees right now.How to read your operation when the metrics look green. The stoplight framework Jeff uses for evaluating efficiency, and why a green department can still have staff running in the red line of mental capacity.The disconnect between the C-suite and the clinical team. Where volume responsibility actually belongs in a healthy program, and where leaders most often misallocate it.Capital decisions in radiation oncology. What separates the programs that get capital right from the ones that do not. Service contracts, software licensing, the ongoing-cost trap, and creative offsets like block leases.AI in oncology operations. A pragmatic take on what AI is actually doing in cancer programs right now versus what is being pitched. Where AI creates time, where it slows things down, and how to think about the patient-side implications.A worked example of how a leadership team handles competing capital requests across service lines, and why “every specialty feels their request is the highest priority” is the room every administrator is in.Yoel and Jeff have known each other for over a decade across the vendor and operator sides of radiation oncology. This is operator-thinking from someone who has lived the job.22 minutes. Worth the time for any administrator, medical director, or system executive running an oncology program in 2026.Medsolve Dynamics: medsolvedynamics.com Reach the team: [email protected]#RadiationOncology #OncologyLeadership #CapitalStrategy #HealthcareExecutive #OncologyOperations

Hiring and retention decisions are landing on the same desks as AI tool decisions, often in the same week. After 20 years on the vendor side, here is the discipline most programs are missing: the same questions you would ask of any capital line, applied to the people on the team and the tools being sold to replace them. medsolvedynamics.com | [email protected]#RadiationOncology #OncologyLeadership #StaffPlanning #FinancialStrategy

From the Medsolve Dynamics conversation with Heather Turner, radiation oncology operator with 14 years from therapist to director. The contracts are not the problem. The autopilot is. medsolvedynamics.com | [email protected]#RadiationOncology #ServiceContracts #VendorNegotiation #OncologyLeadership

The economic case for a LINAC purchase rarely fails at signature. It fails in years two through eight, when the bundled add-ons start collecting service contracts and software renewals. After 20 years on the vendor side, here is what the inside of that conversation looks like, and why bundles are designed exactly this way. medsolvedynamics.com | [email protected]#RadiationOncology #LINAC #CapitalStrategy #VendorNegotiation #OncologyLeadership

Most oncology capital and service negotiations are decided before anyone sits down. Vendor teams map your budget range, rehearse responses to your objections, and identify pricing flexibility they never surface unless you ask the right way.Yoel Bakas spent 20+ years on the vendor side of those conversations at Varian, GE HealthCare, ViewRay, and Mevion before founding Medsolve Dynamics. In this short, he lays out what actually happens in the prep call two days before your meeting, and why harder negotiating rarely changes the outcome.Medsolve Dynamics is a vendor-neutral oncology consulting firm built for programs navigating margin pressure, capital scrutiny, and AI overload.medsolvedynamics.com [email protected]#RadiationOncology #CapitalStrategy #VendorNegotiation #LINAC #OncologyLeadership

After 20 years on the vendor side of oncology at GE HealthCare, ViewRay, and Varian, Yoel Bakas launched Medsolve Dynamics to work from your program side. In this episode, he walks through what Medsolve actually does: capital strategy on LINAC and theranostics purchases, service contract renegotiation before escalator clauses compound, financial case building for theranostics and benign disease service lines before capital is committed, and AI and software evaluation on clinical value and ROI rather than vendor claims. If you have a capital decision, a service contract renewal, a new service line, or an AI evaluation in front of you right now, this is who Medsolve was built for. LINAC capital strategy, oncology vendor negotiation, radiation oncology service contracts, theranostics service line, benign disease radiation therapy, AI in oncology, hospital operations. medsolvedynamics.com | [email protected]

Most oncology service contracts renew automatically unless a specific window is used to renegotiate. Yoel Bakas, founder of Medsolve Dynamics, walks through the specific mechanics of a renewal clock that most program administrators miss until it has already closed — and what a single overlooked provision on page 7 cost one cancer program. Twenty years on the vendor side of oncology means knowing where the escalators, auto-renewals, and quiet cost increases are written into the fine print, and where the leverage lives before the next signature. LINAC service contracts, oncology service renewal, radiation oncology operations, capital strategy. medsolvedynamics.com | [email protected]

The conversation highlights the pitfalls of AI procurement, the consequences of procurement failure, misleading claims in AI sales, and key questions for procurement. It emphasizes the importance of considering adoption requirements and the impact on workflow when purchasing AI solutions.TakeawaysProcurement failureAdoption [email protected]

The conversation explores the critical question of whether decisions hold up at 80% of the current reimbursement, emphasizing the importance of considering this in every capital decision and service renewal.TakeawaysFinancial decisions must consider sustainability at 80% reimbursementEvery purchase decision should be evaluated based on sustainability at 80% [email protected]

A physicist's excitement about a new tool without a clear problem to solve.TakeawaysTool adoption without a clear problemThe allure of new [email protected]

Preparation and Anticipation in NegotiationsTakeawaysPreparation is keyAnticipate [email protected]

The conversation explores the impact of contracts on margins and highlights the importance of paying attention to contract details, especially key provisions that can have a significant financial impact.TakeawaysContract provisions can have significant financial impactImportance of paying attention to contract detailsmedsolvedynamics.com [email protected]

The conversation emphasizes the importance of answering key questions before requesting a quote from a vendor, highlighting the vendor's influence on unanswered questions and the significance of defining the problem before pricing. It also mentions an upcoming presentation at the AMAC® Spring Symposium.TakeawaysAnswer key questions before engaging with vendorsDefining the problem before pricing is [email protected]

Heather Turner has 14 years of experience in radiation oncology. Radiation therapist, operations manager for a new cancer center build, director. In this conversation she and Yoel Bakas talk about the real challenges programs are navigating in 2026. Staffing shortages across therapists, dosimetrists, physicists, and physicians. Workflow breakdowns between radiation oncology, medical oncology, and imaging. The administrative burden of prior authorization. AI tools being purchased before the problem is defined. Service contracts that have not been reviewed since signature. And the pressure of buying equipment when reimbursement just changed the math. [email protected] #RadiationOncology #OncologyOperations #OncologyLeadership #HealthcareStrategy #VendorNegotiation #CapitalStrategy #Theranostics #HospitalOperations

In the context of radiation oncology capital conversations, the focus on price often overshadows other critical factors such as service coverage, software license terms, training, and delivery timelines. Vendors have already modeled the price negotiation and have a floor in mind, leading to a conversation that stays within their designed model.TakeawaysPrice conversation overshadows critical factorsVendors have already modeled price negotiation

Understanding the key provisions in a service contract is crucial to avoid financial losses and unexpected escalations. Four common provisions, including the Evergreen Clause, CPI escalator, bundled software license, and Uptime SLA Definition, can have significant financial implications if not carefully reviewed and understood.TakeawaysKey provisions in service contracts can have significant financial implications.Reading and understanding the entire contract before renewal conversations is crucial.

The conversation delves into the asymmetry in sales conversations, the structural information asymmetry, and the need for program leaders to have support when navigating major capital decisions or service contract renewals.TakeawaysSales conversations are characterized by asymmetryProgram leaders need support in major decisions

Customer experience drives 53% of purchase decisions, not clinical superiority. This is particularly relevant for radiation oncology programs. Programs that document performance gaps can negotiate from a position of strength.TakeawaysCustomer experience is a key factor in purchase decisionsDocumented performance gaps empower negotiation

The conversation delves into the misconceptions and limitations of requesting a quote from a vendor, highlighting the importance of defining success and the problem before engaging in pricing discussions.TakeawaysVendor PerspectiveImportance of Defining Success

Understanding the margin structure of LINAC service contracts and its impact on negotiations.TakeawaysService contracts are highly profitable for vendors.Knowing the margin structure can impact negotiation outcomes.

Oncology programs often have service contracts with major vendors, but lack active tracking of vendor performance. Key performance indicators (KPIs) such as uptime guarantees, response times, maintenance windows, and parts availability are critical levers for negotiation. Documented performance gaps lead to better outcomes than frustration-driven interactions. Leveraging contracts and KPI tracking is essential for program success.TakeawaysVendor performance tracking is crucialDocumented performance gaps lead to better outcomes

The conversation highlights the significant impact of budget cuts on oncology programs, particularly on capital decisions, pre-approved purchases, and service line expansion. It emphasizes the need for reevaluating assumptions and conducting a rigorous review of budget numbers in response to budget cuts.TakeawaysBudget cuts impact capital decisionsReevaluation of assumptions is crucial

The conversation explores the challenges of using AI tools developed by vendors and the importance of understanding support mechanisms. It emphasizes the need to evaluate support gaps before signing up for AI or software solutions.TakeawaysVendor support for AI toolsUnderstanding support mechanisms

The conversation delves into the misconceptions and limitations of requesting a quote from a vendor, highlighting the importance of defining success before engaging in pricing discussions.TakeawaysVendor PerspectiveImportance of Defining Success

The challenges of operationalizing clinical plans and the impact of supply chain disruptions on service lines. The importance of ownership and preparation in the successful launch of new initiatives.TakeawaysOperational challenges impact service linesPreparation and ownership are crucial for successful launches

The conversation covers the importance of starting AI adoption with math, validating model accuracy, challenges with benchmarks, the review and sign-off process, and the impact of AI on business. It emphasizes the need to ask questions before signing AI paperwork to ensure it drives positive change.TakeawaysAI adoption starts with mathValidate model accuracy on relevant dataBenchmarks may not reflect your practiceConsider who needs to review and sign offAI should drive change, not just add costAsk questions before signing AI paperwork

Preparing for a capital meeting involves understanding the negotiation structure and being aware of vendor flexibility. Medsolve can assist in navigating this process effectively.TakeawaysNegotiating within a structured frameworkVendor flexibility and pricing tiers

The conversation covers the importance of understanding and defining constraints, negotiating leverage, and the role of Medsolve in providing a second set of eyes on constraints.TakeawaysDefine your constraintsLeverage comes from understanding and defining your constraints

The conversation covers the preparation for a capital meeting, understanding likely objections, rehearsed responses, negotiating within a pre-mapped structure, negotiating blind, and the value of Medsolve in negotiations.TakeawaysPreparation is key to successful negotiationsUnderstanding the structure of negotiations is crucial for effective outcomes.

Negotiating with vendors requires a deep understanding of business assumptions and leverage points. Preparation is key to successful negotiation.TakeawaysBusiness assumptions are crucialPreparation is key